Opinion|Videos|August 27, 2024
Choosing MDS Therapies: Risk-Based Approaches
Medical experts discuss risk-based approaches to choosing MDS therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Provide a high level overview of treatment approaches for both lower and higher risk MDS.
- What are the key considerations when selecting between different treatment options for lower risk MDS?
- Please include a discussion of when hypomethylating agents (HMAs) would be used in lower risk disease.
Advertisement
Related to this article
Global Burden of Disease data show prevalence fell nearly 30% from 1990 to 2021, yet the number of women affected grew 9.1%.
Logistic regression beats machine learning to predict autoimmune hepatitis recurrence after liver transplantation.
A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.
Itch and skin appearance outranked safety for 300 US adults with chronic hand eczema, but cancer risk came next.
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Systematic review finds no ready blood biomarkers for psoriasis biologics, but IL-17A/IL-17F and beta-defensin 2 show promise for precision medicine.
Geeta Nayyar, MD, MBA, says AI's real health care payoff is cutting administrative friction with clean data and clinical leadership.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Advertisement
Advertisement
Trending on AJMC
1
No Blood Biomarker Is Ready to Pick Psoriasis Therapy
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
4
J&J Oncology Care Index Finds Community Innovation Adoption Gap
5